• linkedin
  • Increase Font
  • Sharebar

    Newer agent efficacious in non-metastatic castration-resistant PCa


    The authors next plan to identify the subset of patients who benefited the most from apalutamide and analyze molecular and circulating blood markers. They also plan to look more closely at the patient-reported outcomes to better understand the patients’ perspective.

    “Not all patients are at the same level of risk of early metastases. So, we will have to have some framework for establishing when and in whom this treatment will be most appropriate,” Dr. Saad explained.

    Kelvin A. Moses, MD, PhD, of Vanderbilt University Medical Center, Nashville, TN, said the results are exciting and provide a new option for this patient population.

    Read - Genetic testing for prostate Ca: What the experts say

    “Men in this setting with a rapidly rising PSA are typically managed with observation, potentially leading to increased anxiety. Apalutamide gives patients and their physicians an oral therapy option in addition to ADT to prolong metastasis-free survival, though there does not appear to be a significant difference in overall survival,” Dr. Moses told Urology Times.

    Apalutamide appears to have a tolerable effect on quality of life. Dr. Moses said these new data will likely lead to the addition of apalutamide in the armamentarium of physicians who manage these complex patients. In addition, he said with further subset analyses it soon may be possible for urologists to offer a much more personalized approach to therapy.

    Dr. Saad has received honoraria from and serves as a consultant/adviser to Janssen Oncology and several other pharmaceutical companies. His institution has also received research funding from Janssen Oncology several other pharmaceutical companies. For full disclosures, click here.

    More from Urology Times:

    Liquid biopsy tests for prostate Ca show low congruence

    Biennial vs. annual prostate biopsies: What the data show

    Prostate Ca test linked to reduction in biopsies

    To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available